Therapy of respiratory syncytial virus infection

Pediatric Infectious Disease Journal

Volumn 19, Issue 8, 2000, Pages 786-790

  DeVincenzo, JOHN P ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN S HOSPITAL   (United States)

Author keywords

Antiviral therapy; Immunocompromised patients; Passive antibody; Respiratory syncytial virus

Indexed keywords

RIBAVIRIN;

ANTIVIRAL ACTIVITY; CASE REPORT; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFANT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; PROGNOSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; RISK ASSESSMENT; SURVIVAL RATE; VIRAL LOAD;

EID: 0033870627     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200008000-00032     Document Type: Review

References (32)

1. Respiratory syncytial virus infections in infants: Quantitation and duration of shedding
2. Nasal quantity of respiratory syncytial virus correlates with disease severity in hospitalized infants
3. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection
4. In vivo inhibition of respiratory syncytial virus by ribavirin
5. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice
6. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease
7. Aerosolized ribavirin treatment of infants with respiratory syncytial virus infection: A randomized double-blind study
8. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infections in infants
9. Ribavirin aerosol for acute bronchiolitis
10. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease
11. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection
12. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis
13. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double-blind, randomized trial
14. Ribavirin for respiratory syncytial virus lower respiratory tract infection: A systematic overview
15. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Thl cytokine production but inhibits Th2 cytokine response
16. Risk of respiratory syncytial virus infection for infants from low income families in relationship to age, sex, ethnic group and maternal antibody level
17. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
18. Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection in cotton rats
19. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group
20. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children
21. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants using humanized monoclonal antibody to RSV F Protein
22. Respiratory viral infections in immunocompetent and immunocompromised persons
23. Respiratory virus infections after marrow transplant: The Fred Hutchinson Cancer Research Center experience
24. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation
25. An outbreak of respiratory syncytial virus in a bone marrow transplant center
26. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model
27. Immunoglobulin administration and ribavirin therapy: Efficacy in respiratory syncytial virus infection of the cotton rat
28. Community respiratory virus infections in immunocompromised patients with cancer
29. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients
30. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin
31. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation
32. Respiratory syncytial virus immune globulin treatment of RSV pneumonia in bone marrow transplant recipients: A compassionate use experience